SCHEMBL5041220

SCHEMBL5041220

C[Sn](C)(C)c1cccc(CCN)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 12/20 0.57
DRD2 P14416 2/20 0.52
DRD1 P21728 2/20 0.52
NOS1 P29475 1/20 0.47
HTR2A P28223 2/20 0.46
CYP2A6 P11509 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
LOXL2 Q9Y4K0 1/20 0.46
HTR7 P34969 1/20 0.46
HTR6 P50406 2/20 0.46
HTR2C P28335 1/20 0.46
PNMT P11086 1/20 0.44
ACHE P22303 2/20 0.41
KDM4E B2RXH2 2/20 0.40
ATM Q13315 1/20 0.40
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
ADRB2 P07550 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5037735 0.83 PNMT (0.48) TAAR1NOS1SMN1; SMN2LOXL2PNMT
SCHEMBL29819459 0.83 PNMT (0.48) TAAR1NOS1SMN1; SMN2LOXL2PNMT
SCHEMBL659100 0.78 TAAR1 (0.70) TAAR1DRD2DRD1NOS1HTR2A
Hydrochloric Acid SCHEMBL3957562 0.75 TAAR1 (0.67) TAAR1DRD2DRD1NOS1HTR2A
SCHEMBL8674936 0.75 ENPP2 (0.45) NOS1
SCHEMBL3057497 0.72 TAAR1 (0.63) TAAR1DRD2DRD1NOS1HTR2A
SCHEMBL387514 0.72 TAAR1 (1.00) TAAR1DRD2DRD1NOS1HTR2A
SCHEMBL44414 0.72 TAAR1 (0.63) TAAR1DRD2DRD1NOS1HTR2A
SCHEMBL15267169 0.72 ACHE (0.35) ACHE
SCHEMBL31318817 0.72 TAAR1 (0.57) TAAR1DRD2DRD1NOS1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7329668-B2 Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-12 US disclosed
US-20040204432-A1 Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US disclosed
WO-2004075846-A2 PYRAZOLOPURINE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME BRISTOL-MYERS SQUIBB COMPANY (US) 2004-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204432-A1 Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same TPMT, HPRT1, TYMP TAAR1 2530/4885DRD2 2050/4885DRD1 2124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.